With their new name to reflect the journey their patients undergo when treated with psychedelic drugs, Tryptamine Therapeutics (ASX: TYP) has confirmed that all patients suffering from fibromyalgia that took their TRP-8802 drug, an oral psilocybin formulation, demonstrated significant pain relief. The study, conducted in collaboration with the University of Michigan (UOM), was presented at
Read More
In July last year, Australia became the first country to legalise ecstasy (MDMA) and magic mushrooms (psilocybin) for mental health disorders, including PTSD and depression. A bold move, it spurred medical businesses into action, seeking the proper approvals and getting the early advantage. At the same time, not all medical professionals were so thrilled, citing
Read More
In Australia, about 43% of people aged between 16 and 85 had experienced a mental disorder at some point as of 2023. Between 2021 and 2022, over 44 million mental health-related meds, largely anti-depressants, were dispensed. While traditional treatments are only about 20 to 30% effective in treating anxiety and depression, recreational cannabis company Melodiol
Read More
As news of billionaire (and controversial) business magnate Elon Musk taking “microdoses of ketamine (a dissociative drug)” to manage depression started doing the rounds, a bunch of divisive arguments popped up—is that just an excuse to justify the use of drugs or is there some hidden potential there? Biotech company Emyria (ASX: EMD) makes a
Read More
Australia has made a groundbreaking decision by becoming the first country to legalise the clinical prescribing of MDMA (ecstasy) and psilocybin (magic mushrooms) for the treatment of specific mental health disorders, including PTSD and treatment-resistant depression. Setting Australia apart as the pioneer in adopting psychoactive-based treatments for mental health, as of 1 July, authorised psychiatrists
Read More
In February 2023, Australia became the first country to accept psychedelics, i.e. hallucinogenic drugs, as medicine. It approved the use of MDMA and psilocybin, typically known as mushrooms and ecstasy, for psychiatric help. Medical cannabis and psychedelics manufacturer Incannex Healthcare (ASX: IHL) wasted no time and announced the launch of the first psychedelic-assisted psychotherapy clinic.
Read More